Company
Purpose
Anonymous Data Shared
When collaboration happened
Epigemonics
Validation of a new technique for improved sensitivity of lung cancer diagnosis in bronchial lavage samples
None – data analysed in-house and results shared.
2010 – 2012
Oxford Gene Technologies
Investigating our ability to find useful DNA mutations routinely collected tumour histology samples (e.g. that might help target treatment or aid prognosis).
None – data analysed in-house and results shared.
2013 – 2015
Inivata Ltd.
Investigating new technology to find useful DNA mutations in blood samples
Cancer diagnosis (type and stage)
2015 – 2017
biocrates life sciences ag
Investigating the potential new technologies for cancer detection based on metabolites in blood
Risk profile and disease status
2016 – 2020
Janssen Pharmaceuticals
Grant support for lung cancer research collaboration on early detection and prevention
Risk profile and disease status
2018 – 2023
Company R*
Grant support to investigate protein biomarkers for improved diagnosis of lung cancer
None – data analysed in-house and results shared.
2020 – 2022
* for reasons of confidentiality and commercial sensitivity, some names are withheld until study completion and publication